Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (OCTOVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03117933|
Recruitment Status : Active, not recruiting
First Posted : April 18, 2017
Last Update Posted : February 24, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Drug: Olaparib Drug: Cediranib Drug: Paclitaxel||Phase 2|
Olaparib is a PARP inhibitor which targets BRCA1/2 mutated tumour cells and cediranib is an anti-angiogenic drug which reduces blood supply to the tumour, suppressing tumour viability. Phase I/II trials of both drugs have shown these are well tolerated alone or in combination in ovarian cancer.
The trial aims to compare the efficacy of the combination and of olaparib alone with paclitaxel chemotherapy and whether the olaparib/cediranib combination is better tolerated thus improving quality of life. Secondly standard paclitaxel chemotherapy must be administered weekly at hospital whereas the olaparib/cediranib combination can be administered at home potentially also improving patient quality of life.
Participants' tumours will be resistant to platinum based therapies. Participants will be randomised into one of the 3 treatment arms after stratification for prior PARP/anti-angiogenic treatments/BRCA status. Participants will be on trial up to 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||139 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomised open label trial with 3 arms, stratified for prior PARP use, prior anti-angiogenic use and BRCA status.|
|Masking:||None (Open Label)|
|Official Title:||Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer|
|Actual Study Start Date :||March 9, 2017|
|Actual Primary Completion Date :||March 12, 2021|
|Estimated Study Completion Date :||June 30, 2022|
Active Comparator: A: Paclitaxel
Paclitaxel, IV weekly, 80mg/m2; until progression
Experimental: B: Olaparib
Olaparib, oral, 300mg twice daily; until progression
Tablet, 100mg and 150mg
Experimental: C: Olaparib and Cediranib
Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
Tablet, 100mg and 150mg
Tablet 15mg and 20mg
- Progression free survival [ Time Frame: up to 18 months ]Progression free survival (PFS), measured as time from date of randomisation to RECIST-defined progression or death from any cause (whichever is first)
- Adverse events [ Time Frame: up to 18 months ]Adverse events using CTCAE v4.03
- Overall Survival [ Time Frame: 12 & 18 months ]Overall Survival
- Objective Response Rate [ Time Frame: up to 18 months ]Objective Response Rate based on RECIST v1.1
- Objective Response Rate [ Time Frame: up to 18 months ]Objective Response Rate based GCIG CA125
- Quality of Life Outcomes [ Time Frame: up to 18 months ]Quality of Life Outcomes based on EORTC-QLQ C30
- Quality of Life Outcomes [ Time Frame: up to 18 months ]Quality of Life Outcomes based on EQ5D
- Quality of Life Outcomes [ Time Frame: up to 18 months ]Quality of Life Outcomes based on OV28.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||16 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Female patients, age ≥ 16 years with relapsed epithelial ovarian, primary peritoneal or fallopian tube cancer who have relapsed within 12 months of previous platinum-based therapy. Their most recent chemotherapy does not have to have been platinum-based.
- Patients can have received prior PARP inhibitor, but there must be a > 6 month interval since treatment.
- Patients can have received prior antiangiogenic therapy, but there must be a > 6 month interval since treatment; except for bevacizumab where a 6 week interval is required.
- Measurable disease by RECIST Version 1.1 performed in past 4 weeks. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.
- Sufficient archival tissue confirming histological diagnosis available.
- ECOG PS 0-2
- Able to swallow and retain oral medications.
- Life expectancy > 12 weeks in terms of disease related mortality
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Written (signed and dated) informed consent prior to any study specific procedures and be capable of co-operating with protocol.
Patients must have
• Haemoglobin ≥ 9.0 g/dL and no blood transfusions in the 28 days prior to randomisation
Patients must have normal organ and bone marrow function measured within 14 days prior to administration of study treatment as defined below:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count > 100 x 109/L
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN
- Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN) or calculated creatinine clearance >50 ml/min calculated using Cockroft-Gault, Jelliffe or Wright (see Appendix 4)
- Urine dipstick for proteinuria <2+. If urine dipstick is ≥ 2+ on two occasions more than one week apart then a 24-hour urine must demonstrate ≤ 1 g of protein in 24 hours or protein/creatinine ratio < 1.5.
- Received previous single agent weekly paclitaxel for relapsed disease.
Pregnant or breast-feeding women or women of childbearing potential unless effective methods of contraception are used during the trial and for 6 months after stopping treatment. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. Pregnancy test will be performed monthly in women of child bearing potential.
Postmenopausal is defined as:
- Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
- LH and FSH levels in the post-menopausal range for women under 50,
- radiation-induced oophorectomy with last menses >1 year ago,
- chemotherapy-induced menopause with >1 year interval since last menses, or surgical sterilisation (bilateral oophorectomy or hysterectomy).
- Treatment with any other investigational agent, systemic chemotherapy, or participation in another interventional clinical trial within 28 days prior to enrolment.
- Radiotherapy within 2 weeks from the last dose prior to study treatment
- Started a stable dose of bisphosphonates for bone metastases less than 4 weeks prior to treatment with study drug e.g. patient is eligible and can continue to take bisphosphonates if these were started at least 4 weeks prior to treatment with study drug.
- Concomitant use of known CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.
- Concomitant use of potent inducers of CYP3A4 such as rifampicin, carbamazepine, phenobarbital, phenytoin and St. John Wort.
- Persistent toxicities (>=CTCAE grade 2) caused by previous cancer therapy with the exception of alopecia.
- Resting ECG with QTc > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
- Blood transfusions within 1 month prior to study start
- Patients with myelodysplastic syndrome/acute myeloid leukaemia.
Patients with symptomatic, untreated, uncontrolled brain or meningeal metastases or tumour.
a. A scan to confirm the absence of brain metastases is not required. b. Patients with radiological evidence of stable brain metastases are eligible, providing that they are asymptomatic and: i. Do not require corticosteroids, or ii. Have previously been treated with corticosteroids, with clinical and radiological evidence of stabilisation at least 10 days after discontinuation of steroids iii. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 28 days prior to treatment.
- Major surgery within 14 days of starting study treatment
- Patients who have not recovered from any effects of any major surgery.
- Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan
- Any psychiatric disorder that prohibits obtaining informed consent.
Left Ventricular Ejection Fraction (LVEF) < institutional lower limit of normal, when:
i. Prior treatment with anthracyclines (excluding liposomal doxorubicin) ii. Prior treatment with trastuzumab iii. A NYHA classification of II controlled with treatment (see Appendix 2) iv. Prior central thoracic RT, including RT to the heart v. History of myocardial infarction within the prior 12 months
- Poorly controlled hypertension (persistently elevated > 150/100mmHg, either systolic or diastolic or both, despite anti-hypertensive medication)
- History of inflammatory bowel disease
- History of cerebrovascular accident (including transient ischaemic attacks) within last 12 months.
- Gastro intestinal impairment that could affect ability to take, or absorption of, oral medicines including sub- acute or complete bowel obstruction
- Evidence of severe or uncontrolled cardiac disease
- Evidence of active bleeding or bleeding diathesis. Defined as significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks)
- Known treatment-limiting hypersensitivity to cediranib, olaparib, paclitaxel or any of its excipients
- Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
- Any other active malignancy, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions, requiring treatment/or whose prognosis will prevent readout from trial endpoints.
- Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV.
28 Immunocompromised patients e.g., patients who are taking immunosuppressive drugs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117933
|Belfast City Hospital|
|Belfast, County Antrim, United Kingdom, BT9 7AM|
|Mount Vernon Cancer Centre|
|Northwood, Middlesex, United Kingdom|
|City Hospital Nottingham|
|Nottingham, Nottinghamshire, United Kingdom, NG5 1PB|
|Royal Surrey County Hospital|
|Guildford, Surrey, United Kingdom, GU2 7XX|
|Royal United Hospital|
|Bath, United Kingdom|
|Cardiff, United Kingdom|
|Beatson West of Scotland Cancer Centre|
|Glasgow, United Kingdom|
|Clatterbridge Cancer Centre|
|Liverpool, United Kingdom|
|London, United Kingdom, EC1A 7BE|
|London, United Kingdom, W12 0HS|
|Royal Marsden Chelsea & Sutton|
|London, United Kingdom|
|University College London|
|London, United Kingdom|
|Manchester, United Kingdom|
|Oxford, United Kingdom, OX3 7LE|
|Responsible Party:||University of Oxford|
|Other Study ID Numbers:||
2016-000559-28 ( EudraCT Number )
16/LO/2150 ( Other Identifier: Research Ethics Committee )
|First Posted:||April 18, 2017 Key Record Dates|
|Last Update Posted:||February 24, 2022|
|Last Verified:||February 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Poly(ADP-ribose) Polymerase Inhibitors
Protein Kinase Inhibitors